Alterity’s ATH434 Slows MSA Decline 41% in Phase 2, Eyes Pivotal Trial
Alterity Therapeutics has reported new Phase 2 data for ATH434 demonstrating disease-modifying activity in Multiple System Atrophy patients, with the 50 mg dose achieving a 41% relative treatment effect versus placebo on the MuSyCA composite scale at Week 52 (p=0.034). The analysis was presented in a Late Breaking Science Session at the American Academy of Neurology Annual Meeting in Chicago on 22 April 2026.
ATH434 demonstrates disease-modifying signal in pivotal MSA analysis
The new analysis centres on MuSyCA (MSA Combined Outcome Assessment), a recently developed composite scale integrating 11 items from both daily function (UMSARS I) and neurological examination (UMSARS II) components. Placebo participants worsened by approximately +9.7 points over 52 weeks on MuSyCA, confirming the scale’s sensitivity to disease progression over the study period.
ATH434 treatment produced a −1.9 point change at the 75 mg dose and −4.0 points at the 50 mg dose (p=0.034, relative treatment effect 41%) at Week 52. These improvements were observed across both daily function and neurological examination domains, reinforcing the previously reported activity on modified UMSARS Part I.
A separate Mixed Models for Repeated Measures (MMRM) statistical analysis showed ATH434 slowed disease progression on modified UMSARS I versus placebo by −3.1 points at 75 mg (35% relative treatment effect) and −4.7 points at 50 mg (53% relative treatment effect, p=0.029).
The convergence of positive signals across multiple validated assessment scales strengthens ATH434’s clinical profile ahead of Phase 3 regulatory engagement. For rare disease biotechs, demonstrating reproducible efficacy across multiple endpoints represents the critical value inflection point that de-risks pivotal trial design and attracts partnership interest.
David Stamler, CEO
“In this rapidly progressive disease, ATH434 shows consistent evidence of efficacy by slowing functional decline on the newly described MuSyCA scale, which reinforces the efficacy observed on the established UMSARS Part I scale. In aggregate, these data reinforce the potential of ATH434 as a disease-modifying therapy for MSA.”
When big ASX news breaks, our subscribers know first
Understanding Multiple System Atrophy and the unmet medical need
Multiple System Atrophy is a rare, rapidly progressive neurodegenerative disease characterised by failure of the autonomic nervous system and impaired movement. The disease causes profound disability through a variable combination of slowed movement and/or rigidity, autonomic instability affecting involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and coordination that predisposes to falls.
A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia (the support cells of the central nervous system) and neuron loss in multiple brain regions. MSA affects up to 50,000 individuals in the United States. While some symptoms can be managed with medications, currently there are no drugs able to slow disease progression and there is no cure.
This treatment gap creates a significant commercial opportunity. First-to-market advantage in rare disease with an established patient population and clear regulatory pathway via Orphan Drug Designation positions ATH434 as a potentially transformative therapy in a market with no disease-modifying alternatives.
MuSyCA scale validates clinical trial methodology
A new framework for MSA assessment
MuSyCA represents a new framework for MSA outcome assessment by integrating patient-reported function with clinical examination. The scale was developed by the NIH-funded “Clinical Trial Readiness for MSA Study Group” in a collaborative effort with four academic centres in the US and Europe, patient advocacy groups, and pharmaceutical companies.
The scale demonstrated robust sensitivity to disease progression over the 52-week study period, with placebo participants showing measurable worsening. Future iterations are planned to incorporate neurofilament light chain (NfL), imaging, and objective performance tests as a comprehensive platform for detecting clinically meaningful changes over time.
| Treatment Arm | MuSyCA Change (Week 52) | Relative Treatment Effect | Statistical Significance |
|---|---|---|---|
| Placebo | +9.7 points | — | — |
| ATH434 75 mg | −1.9 points | — | — |
| ATH434 50 mg | −4.0 points | 41% | p=0.034 |
Regulatory bodies favour validated, sensitive outcome measures backed by academic and industry collaboration. MuSyCA’s development pedigree and demonstrated ability to detect treatment effects strengthen the credibility of Phase 3 trial design, potentially accelerating regulatory discussions and reducing development risk.
ATH434’s mechanism and regulatory positioning
ATH434 is an oral iron chaperone designed to reduce iron accumulation and inhibit abnormal protein aggregation associated with neurodegeneration. In preclinical models, the compound has been shown to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, ATH434 has potential application across Parkinson’s disease and various Parkinsonian disorders including MSA.
The compound has secured multiple regulatory designations from both US and European authorities:
- FDA Fast Track Designation
- FDA Orphan Drug Designation
- European Commission Orphan Drug Designation
Fast Track status enables more frequent FDA interactions throughout development, while Orphan Drug Designation provides seven years of market exclusivity upon approval, potential tax credits on clinical trial costs, and exemption from prescription drug user fees. These designations materially de-risk the development pathway and enhance the commercial opportunity.
The Company is preparing to initiate a Phase 3 pivotal trial in MSA using this reinforced clinical profile as the regulatory foundation.
The next major ASX story will hit our subscribers first
What comes next for Alterity
Alterity’s immediate priority is Phase 3 engagement with regulators, leveraging the expanded evidence package from multiple Phase 2 assessments. The Company has completed two Phase 2 trials that collectively establish ATH434’s clinical and commercial potential:
- Randomised, double-blind, placebo-controlled Phase 2 trial showing clinical efficacy
- Open-label Phase 2 biomarker trial in advanced MSA reinforcing results
- Target engagement confirmed via key biomarkers
- Favourable safety profile established
Positive results from the randomised, double-blind, placebo-controlled Phase 2 clinical trial demonstrated robust clinical efficacy, target engagement as indicated by key biomarkers, and a favourable safety profile. Positive data from a second Phase 2 open-label biomarker trial in patients with more advanced MSA reinforced these results.
ATH434 now has demonstrated reproducible efficacy across multiple validated outcome measures, biomarker evidence of target engagement, and an established safety profile across two independent patient cohorts. This positions the programme for regulatory discussions on pivotal trial design.
Beyond MSA, Alterity maintains a broader drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The platform provides long-term optionality beyond the lead programme.
The transition from Phase 2 to Phase 3 regulatory discussions represents a near-term catalyst. Positive regulatory engagement could trigger partnership interest from larger pharmaceutical companies seeking late-stage rare disease assets, or necessitate a capital raise to fund pivotal trial execution.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving biotech announcements delivered straight to your inbox the moment they break.